Primary information |
---|
ID | 1005 |
Peptide Name | kalata B1 mutants [T20K] |
Sequence | GLPVCGETCVGGTCNTPGCKCSWPVCTRN |
Length | 29 |
Chirality | L |
N-terminal Modification | Addition of Cysteine |
C-terminal Modification | Thioester linker |
Chemical Modification | Three Disulfide linkage (CI-CIV, CII-CV and CIII-CVI) |
Linear/ Cyclic | Cyclic (head to tail |
Nature | Synthetic |
Source of Origin | NA |
Target | Reduction of the IL-2 surface receptor CD25 expression (79%±10 after 24 hrs and 46%±18 after 36 hrs), also reduces TNF-α expression (23%±11) |
Mechanism of Action | Suppress T-cell polyfunctionality and arrest the proliferation of immune-competent cells through inhibiting IL-2 biology at more than one site as IL-2) surface receptor as well as IL-2 cytokine secretion and IL-2 gene expression. |
In vitro/In vivo | In vitro |
Cell Line | Human peripheral Lymphocytes |
Inhibition Concentartion | 1.9±0.6 micromolar for Lymphocytes (PBMCs) |
In vivo Model | NA |
Assay | Cell Proliferation assay, Ca2+ release assay, Cytokines release assay |
Lethal Dose | NA |
Combination Therapy | NA |
Pubmed ID | 23840803 |
Year of Publication | 2013 |
3-D Structure | NA |